The new target population is much smaller than Fulcrum previously envisioned. But some analysts expressed optimism in the drugs prospects. We believe there could be a need especially among those with severe disease that could benefit from reduced recurring events andor a functional cure wrote Leerink Partners analyst Joseph Schwartz in a note to investors Tuesday